Clinical Trial Update: Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating ornithine phenylacetate in patients with cirrhosis and upper gastrointestinal bleeding has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Gastrointestinal Bleeding

Drugs mentioned

• Ornithine phenylacetate (ornithine phenylacetate)

Snippet

Sponsor: Hospital Universitari Vall d'Hebron Research Institute | Conditions: Gastrointestinal Bleeding, Cirrhosis | Phase 2, Phase 3 | Status: COMPLETED